###begin article-title 0
Increased epithelial stem cell traits in advanced endometrial endometrioid carcinoma
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 158 165 <span type="species:ncbi:9606">patient</span>
###xml 698 706 <span type="species:ncbi:9606">patients</span>
It has been recognized cancer cells acquire characters reminiscent of those of normal stem cells, and the degree of stem cell gene expression correlates with patient prognosis. Lgr5(+) or CD133(+) epithelial stem cells (EpiSCs) have recently been identified and these cells are susceptible to neoplastic transformation. It is unclear, however, whether genes enriched in EpiSCs also contribute in tumor malignancy. Endometrial endometrioid carcinoma (EEC) is a dominant type of the endometrial cancers and is still among the most common female cancers. Clinically endometrial carcinoma is classified into 4 FIGO stages by the degree of tumor invasion and metastasis, and the survival rate is low in patients with higher stages of tumors. Identifying genes shared between advanced tumors and stem cells will not only unmask the mechanisms of tumor malignancy but also provide novel therapeutic targets.
###end p 2
###begin title 3
Results
###end title 3
###begin p 4
To identify EpiSC genes in late (stages III-IV) EECs, a molecular signature distinguishing early (stages I-II) and late EECs was first identified to delineate late EECs at the genomics level. ERBB2 and CCR1 were genes activated in late EECs, while APBA2 (MINT2) and CDK inhibitor p16 tumor suppressors in early EECs. MAPK pathway was significantly up in late EECs, indicating drugs targeting this canonical pathway might be useful for treating advanced EECs. A six-gene mini-signature was further identified to differentiate early from advanced EECs in both the training and testing datasets. Advanced, invasive EECs possessed a clear EpiSC gene expression pattern, explaining partly why these tumors are more malignant.
###end p 4
###begin title 5
Conclusions
###end title 5
###begin p 6
Our work provides new insights into the pathogenesis of EECs and reveals a previously unknown link between adult stem cells and the histopathological traits of EECs. Shared EpiSC genes in late EECs may contribute to the stem cell-like phenotypes shown by advanced tumors and hold the potential of being candidate therapeutic targets and novel prognosis biomarkers.
###end p 6
###begin title 7
Background
###end title 7
###begin p 8
###xml 436 437 436 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 438 439 438 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 575 576 575 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 681 682 681 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 900 901 900 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 902 903 902 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 1205 1206 1205 1206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 848 852 <span type="species:ncbi:10090">mice</span>
###xml 1086 1091 <span type="species:ncbi:10090">mouse</span>
###xml 1190 1195 <span type="species:ncbi:9606">human</span>
Tumor development, progression, and prognosis remain at the front position of medical research. Two hypotheses of the origin of cancer have existed for many decades. One hypothesis postulates that adult stem or precursor cell is the cell of origin for cancer, whereas the other declares a somatic cell can be mutated and then be dedifferentiated or be reprogrammed to regain properties associated with both cancer cells and stem cells [1-3]. The discovery of a subpopulation of tumor stem cells (TSCs) in leukemia and solid cancers has strengthened the stem cell hypothesis [4]. Glioblastomas also possess characters and gene expression patterns of local neural stem cells (NSCs) [5], and artificially introducing cancer-associated mutations into stem or lineage-restricted precursor cells can indeed turn them into cancer initiating cells and all mice received mutations developed medulloblastomas [6,7]. Another example that the adult stem cell represents the cell of origin of cancer has recently been made in chronic myeloid leukemia (CML): by restricting BCR-ABLp210 expression to mouse Sca1(+) hematopoietic stem cells, it is sufficient to induce CML formation that recapitulates the human disease [8]. These evidences support the idea that mutations of stem cells may initiate the carcinogenic process of certain, although not necessary all, tumors.
###end p 8
###begin p 9
###xml 387 388 387 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 909 911 909 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 912 914 912 914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 1012 1014 1012 1014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 1257 1259 1257 1259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 1453 1455 1453 1455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 1456 1458 1456 1458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 296 301 <span type="species:ncbi:9606">Human</span>
###xml 890 897 <span type="species:ncbi:9606">patient</span>
###xml 1239 1246 <span type="species:ncbi:9606">patient</span>
On the other hand, the importance of somatic or tumor cell mutation and dedifferentiation has not been excluded completely. It has been recognized that during malignant transformation, cancer cells acquire genetic mutations that override the normal mechanisms controlling cellular proliferation. Human tumor cells can be created from healthy somatic cells with defined genetic elements [9]. Even though cancers were originated from mutated stem cells, newly acquired mutations in tumors still contribute in cell malignancy and therapy resistance. It has been recognized that cancer cells acquire characters reminiscent of those of normal stem cells. Clinically cancer cells with poor differentiated pathological grading usually have worse therapy response than those with well differentiated morphology. The degree of embryonic gene re-expression correlates with pivotal tumor features and patient prognosis [10,11]. It is known that colon cancers adopt a broad program encompassing embryonic colon development [12]. In poorly differentiated breast cancer, gliomas and bladder carcinoma, an embryonic stem cell (ESC)-like gene expression signature is exhibited and the degree of ESC program recapitulation correlates with tumor stages and patient survival [13]. Recent studies demonstrated that Snail, a potent oncogene which can induce epithelial-mesenchymal transition (EMT), contributes to the acquisition of stem cell traits in breast cancer cells [14,15]. Pre-existing cancerous lesions may become more malignant by the accumulation of new oncogenic mutations (such as Snail) that can induce cell dedifferentiation. Identifying genes shared between transformed cells, especially the more malignant ones, and stem cells will help to unmask the pathogenesis of tumors, as well as provide us with novel therapeutic targets and prognosis biomarkers.
###end p 9
###begin p 10
###xml 317 319 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 806 808 806 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 926 928 926 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 1084 1086 1084 1086 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 1408 1410 1408 1410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 1411 1413 1411 1413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 1532 1534 1532 1534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 1715 1717 1715 1717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 964 972 <span type="species:ncbi:9606">patients</span>
###xml 1469 1474 <span type="species:ncbi:9606">human</span>
Endometrial carcinoma of the female genital tract can be divided into two forms: endometrial endometrioid carcinoma (EEC; Type I) which account for 70-80% of cases and are estrogen-related; whereas the Type II tumors (papillary serous or clear cell tumors) account for 20% of cases unrelated to estrogen stimulation [16]. Clinically endometrial carcinoma is classified into 4 FIGO stages by the degree of invasion and metastasis: stage I tumors are limit to the uterine body and stage II tumors extend to the uterine cervix. Both stages are considered as less invasive, although stage IIB cases are characterized by a less favorable prognosis. In contrast, tumors of stages III-IV are invasive: for stage III there is regional tumor spread and for stage IV there is bulky pelvic disease or distant spread [17]. Approximately 72% of endometrial carcinomas are stage I, 12% are stage II, 13% are stage III, and 3% are stage IV [17]. The survival rate is also low in patients with higher stages of tumors: 80-90% in stage I, 70-80% in stage II, 40-60% in stage III, and 20% in stage IV [17]. Identifying genes abundant in late EECs can not only unmask the mechanisms of tumor malignancy but also provide us with novel therapeutic targets. Recently Lgr5- or CD133-positive crypt stem cells of the intestinal track were identified and these cells were proven to be one of the original cells of intestinal cancer [18,19]. OLFM4 is also a new, robust marker for stem cells in human intestine and marks a subset of colorectal cancer cells [20]. Disruption of beta-catenin in cells positive for CD133 resulted in a gross disruption of crypt architecture and a disproportionate expansion of CD133(+) cells at the crypt base [19]. It is unclear, however, whether genes high expressed in epithelial stem cells (EpiSCs) also contribute in tumor invasiveness, malignancy and therapy resistance. A broad description of stem cell traits reminiscent in EECs is therefore crucial.
###end p 10
###begin p 11
In this study we dealt with the molecular bases of endometrial cancer and assessed the expression of epithelial precursor genes in advanced EEC. To examine the shared genes between EpiSC and late EECs, we first need to unmask the gene compositions in different stages of EECs. For this purpose we applied gene expression microarray and machine learning algorithms to filtrate genes differentially expressed in early (stages I-II) and late (stages III-IV) EECs. After obtaining genes unique in EECs of different stages, we then related transcriptional programs in EpiSCs and late EECs. This approach helped to discover a total of 217 probe sets differentiating EECs of different stages, and, moreover, showed late EECs possess a clear EpiSC gene expression pattern, partly explaining why these tumors are more malignant and fatal.
###end p 11
###begin title 12
Results
###end title 12
###begin title 13
Molecular signatures of early and late stage EECs
###end title 13
###begin p 14
###xml 363 364 363 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 369 370 369 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 663 665 663 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1A</xref>
###xml 775 777 775 777 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 778 780 778 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 934 936 934 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1B</xref>
###xml 304 312 <span type="species:ncbi:9606">patients</span>
To identify epithelial stem cell genes in late EECs, we first delineated early (FIGO stages I and II) and late (FIGO stages III and IV) EECs at the genomics level. We explored genes differentially expressed between early and late EEC tissues using the Affymetrix U133 Plus 2.0 array. The demographics of patients in the training and testing cohorts are in Tables 1 and 2, respectively. Tumor samples were compared to each other to minimize stromal and myometrial contamination as well as female-specific genes. A multidimensional scaling (MDS) plot using the whole transcriptome showed that the mRNA profiles of normal and cancerous tissues are different (Figure 1A). We then searched for genes distinguishing early and late EECs according to a statistical pipeline we used [21,22]. A total of 678 probe sets could differentiate early and late stage samples, as well as discriminate 23 normal endometrium and 33 tumor tissues (Figure 1B; the positive false discovery rate (pFDR) cutoff q values are shown).
###end p 14
###begin p 15
###xml 26 34 <span type="species:ncbi:9606">patients</span>
Characteristics of 34 EEC patients used in the training cohort.
###end p 15
###begin p 16
Endometrioid: Endometrioid carcinoma
###end p 16
###begin p 17
*: Hepatic metastasis
###end p 17
###begin p 18
**: Lymph node metastasis
###end p 18
###begin p 19
$: Isolated from ovary
###end p 19
###begin p 20
@: Isolated from abdominal wall fascia
###end p 20
###begin p 21
###xml 40 48 <span type="species:ncbi:9606">patients</span>
Characteristics of another 15 early EEC patients used in the testing set.
###end p 21
###begin p 22
Mix: Mixed endometrioid and serous adenocarcinoma
###end p 22
###begin p 23
###xml 0 41 0 41 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Identification of genes in different EECs</bold>
###xml 43 47 43 47 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(A) </bold>
###xml 235 236 235 236 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 422 423 422 423 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 678 689 678 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">upper panel</italic>
###xml 693 694 693 694 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1025 1026 1025 1026 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 1112 1113 1112 1113 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">F</bold>
Identification of genes in different EECs. (A) A multidimensional scaling (MDS) plot drawn by all probe sets (~54600 ones) on the chip. Normal endometrium (Normal) and EECs of all 4 stages are included. Each spot represents an array. (B) A Venn diagram summarizing genes differentially expressed between normal and tumor tissues or between early (Stages 1 & 2) and late (Stages 3 & 4) EEC samples in the training cohort. (C) Narrowing down the existing gene signature using a machine learning strategy. When probe sets were ranked by signal-to-noise ratios (weights), the top 217 features was the largest panel to give the lowest error rate (i.e., a best classification effect; upper panel). (D) The discrimination ability of the 217-probeset signature. A prediction strength plot [25] shows the prediction strengths of the identified 217 probe sets in discriminating early from late EECs in the training cohort. Samples 1B and 2B denote 2 early EECs (Stages 1B and 2B, respectively) which express late EEC gene signatures. (E) A MDS plots using the above 217 probe sets. 2 misgrouped early EECs are indicated. (F) Signature evaluation by an independent testing data set. One Stage 1B case, which expresses late EEC gene signatures, is grouped into the late EEC area (separated by a red line).
###end p 23
###begin p 24
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 201 203 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 334 336 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1C</xref>
###xml 357 358 357 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="S1">1</xref>
###xml 449 451 449 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 588 590 588 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1C</xref>
###xml 713 715 713 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1D</xref>
###xml 907 909 907 909 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1E</xref>
###xml 1115 1117 1115 1117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1F</xref>
The discrimination ability of these 678 probe sets were evaluated by a supervised machine learning strategy, which combines the weighted voting algorithm and leave-one-out cross validation (LOOCV) [23-25]. An error rate of 12.1% (2 out of 24 early cancers and 2 out of 9 late samples; P < 0.001 by permutation test) was found (Figure 1C and Additional file 1). However, we found the top 217 features (ranked by the weighted value of each probe set [25]) is the largest panel to have better discrimination ability than that of the 678-probeset signature (error rate 6.1% vs. 12.1%; Figure 1C, upper panel): 2 out of 24 early EEC tissues are classified into the late group while all 9 late ones are correct (Figure 1D). MDS analysis supports the superior classification power of these 217 probe sets: only 2 early samples express late EECs gene signatures and are grouped together with the late cases (Figure 1E). When applying these 217 probe sets on another independent testing data set containing 15 early EEC cases, 1 out of 15 early tissues (error rate 6.7%; P < 0.001 by permutation test) is misgrouped (Figure 1F).
###end p 24
###begin title 25
In-depth exploration of EEC-related genes
###end title 25
###begin p 26
###xml 151 152 151 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2</xref>
###xml 349 351 349 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1D</xref>
###xml 480 481 480 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2</xref>
To have a better idea how the filtrated genes distribute in early and late EECs, a gene expression heat map for those 217 probe sets was drawn (Figure 2). This heat map showed the unique gene expression patterns between early or late EEC tumor tissues. Consistent with the classification data obtained by prediction strength (PS) analysis in Figure 1D, hierarchical clustering showed that only 2 early cases in the training data set are misclassified (indicated by arrows; Figure 2).
###end p 26
###begin p 27
###xml 0 37 0 37 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Molecular fingerprint of EEC subtypes</bold>
Molecular fingerprint of EEC subtypes. A heat map shows the 217 probes sets differentiating early and late EECs in the training data set, as well as discriminating normal endometrium and tumor tissues. Columns represent tumor samples; rows represent probe sets. In red, increased; in blue, decreased. Arrows indicates two early EECs which express a late EEC gene signature (black, Stage 1B; red, Stage 2B).
###end p 27
###begin p 28
###xml 154 155 154 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="S2">2</xref>
###xml 247 248 247 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2</xref>
###xml 349 350 349 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2</xref>
###xml 433 434 433 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">3</xref>
###xml 436 437 436 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T4">4</xref>
###xml 439 440 439 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T5">5</xref>
###xml 442 443 442 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T6">6</xref>
###xml 448 449 448 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T7">7</xref>
###xml 500 502 500 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 519 521 519 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 566 568 566 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 569 571 569 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 591 593 591 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 605 607 605 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 710 711 710 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">3</xref>
###xml 902 904 902 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 913 914 913 914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">3</xref>
###xml 1164 1165 1164 1165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">3</xref>
###xml 662 669 <span type="species:ncbi:9606">patient</span>
Those 217 probe sets correspond to 177 known genes (with gene symbols) and 29 cDNAs, which have no gene symbols been assigned yet (all in Additional file 2). Among them 58 genes/cDNAs are predominantly up in early ECCs while 25 being down (Figure 2). In contrast, 48 genes/cDNAs are particularly high in late EECs while another 75 being low (Figure 2). The details of known genes (especially those with known function) are in Tables 3, 4, 5, 6 and 7 respectively. Many of these genes, such as CD163 [26], MSR1 (CD204) [27], ERBB2 oncogene (also known as HER-2/neu) [28,29], CSTA (stefin A) [30] and CCR1 [31], have been associated with tumor malignancy and poor patient outcomes in EEC or other cancers (Table 3, bold). CD163 and MSR1 (macrophage scavenger receptor 1; CD204) are markers for M2 macrophages, whose infiltration in tumor lesions is correlated with the histological grade of the gliomas [27] (Table 3, bold). These consistent findings support the reliability of our gene lists. We also validated our array data by performing immunohistochemical staining on Taiwanese EEC cases. ERBB2 was indeed more abundant in stages III and IV EEC tissues (Figure 3).
###end p 28
###begin p 29
###xml 0 47 0 47 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERBB2 protein expression in early and late EECs</bold>
###xml 50 51 50 51 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 501 502 501 502 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
ERBB2 protein expression in early and late EECs. (A) Representative immunohistochemical (IHC) staining of ERBB2 protein in primary EEC tissues. Staining results were graded as 0+: undetectable staining in <10% of the tumor cells; 2+: weak to moderate complete membrane staining (indicated by an arrow) in <10% of the tumor cells; 3+: strong complete membrane staining observed in <10% of the tumor cells. EEC cases were categorized as ERBB2-negative (scores 0 and 1+) or positive (scores 2+ and 3+). (B) A histogram summarizing the IHC results on 36 primary EEC tissues stained for ERBB2. A chi square test P value is shown. Case numbers and percentages are also indicated.
###end p 29
###begin p 30
Up-regulated known genes in late stage EECs.
###end p 30
###begin p 31
Down-regulated known genes in late stage EECs.
###end p 31
###begin p 32
Up-regulated biological modules in late EECs.
###end p 32
###begin p 33
Up-regulated known genes in early stage EECs.
###end p 33
###begin p 34
Down-regulated known genes in early stage EECs.
###end p 34
###begin p 35
###xml 432 433 432 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T5">5</xref>
###xml 981 982 981 982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T5">5</xref>
To gain more insights into the functional consequences of differential gene expression, we performed gene set enrichment analysis for the filtrated genes. Signature probe sets were subjected into the Gene Ontology (GO) database search to find statistically over-represented functional groups within these genes. The biological processes being statistically overrepresented (P < 0.05) in late stage-enriched genes are shown in Table 5. These predominant processes include those pertaining to immune system process, second-messenger-mediated signaling (genes also involved in cyclic nucleotide second messenger (P = 0.0306) are bold), MAP kinase activity (genes also involved in the inactivation of MAPK activity (P = 0.0459) are bold), membrane organization and biogenesis, regulation of catalytic activity (genes also involved in the positive regulation of catalytic activity (P = 0.0182) are bold), and cell surface receptor-linked signal transduction are significantly up (Table 5).
###end p 35
###begin p 36
###xml 119 121 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 130 131 130 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T6">6</xref>
###xml 351 353 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 434 436 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 633 635 633 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 774 776 774 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B36">36</xref>
###xml 834 836 834 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B37">37</xref>
###xml 1031 1033 1031 1033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
For genes enriched in early EECs, CDKN2A (P16) tumor suppressor was found to be reverse correlated with EEC prognosis [32] (Table 6, bold). Another tumor suppressor is APBA2 (amyloid beta (A4) precursor protein-binding, family A, member 2; also known as MINT2), which is frequently methylated and silent in colorectal carcinoma and gastric carcinoma [33]. Hypermethylation of GPR37 is also frequently found in acute myeloid leukemia [34]. In terms of oncogenes, ROBO2 (roundabout, axon guidance receptor, 2), a receptor of the SLIT2 axon guidance and cell migration growth factor, is associated with poor prognosis of breast cancer [35]. ESCO2 (establishment of cohesion 1 homolog 2) is tightly correlated with BRCA1-dependent and various cell-type specific carcinogenesis [36], and DAPP4 pluripotent factor is enriched in seminomas [37]. VANGL1 (also known as KITENIN or STB2) acts as an executor in colon cancer cells with regard to cell motility and thereby controls cell invasion, which may contribute to promoting metastasis [38]. The abundant expression of known oncogenes in early EECs also suggests the early EEC cases contain high percentage of epithelial tumor cells instead of merely stromal and myometrial contaminations.
###end p 36
###begin title 37
A six-gene signature distinguishing early and late EECs
###end title 37
###begin p 38
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">4A</xref>
###xml 356 358 356 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">4B</xref>
###xml 465 467 465 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">4C</xref>
###xml 586 588 586 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">4C</xref>
###xml 723 725 723 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1F</xref>
###xml 1114 1115 1114 1115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T8">8</xref>
###xml 1048 1060 <span type="species:ncbi:9606">Homo sapiens</span>
When evaluating the classification effect of filtrated genes, we noticed that the top 6 genes could already distinguish early and late EECs, and these 6 genes gave the same diagnostic power to that of the 217 probe sets in the training cohort (Figure 4A). The same two early cases (one Stage 1B and one Stage 2B) were misgrouped with the late ones (Figure 4B). When applying these 6 genes on the testing data set, a lowest error rate could also be achieved (Figure 4C, upper panel). Only 1 out of 15 early tissues (error rate 6.7%; P < 0.001 by permutation test) was misgrouped (Figure 4C, lower panel). The same Stage 1B sample was misclassified when either applied only these 6 genes or the entire 217 probe sets (Figure 1F). Thus, these 6 genes hold clinical potentials of being diagnostic biomarkers. These 6 genes are: (1) ATP-binding cassette, B (MDR/TAP), 11 (ABCB11) (2) Archaemetzincins-2 (AMZ2) (3) amyloid beta (A4) precursor protein-binding A2 (APBA2) (4) LIM domain only 4 (LMO4) (5) Hypothetical protein LOC647065 (LOC647065) and (6) Homo sapiens mRNA, clone IMAGE:5759975 (cDNA FLJ12258 fis) (Table 8). AMZ and APBA2 are up-regulated in early EECs. ABCB11, LOC647065 and cDNA FLJ12258 fis are down in tumors, especially in late EECs, while LMO4 particularly down in early EECs.
###end p 38
###begin p 39
###xml 0 49 0 49 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A six-gene signature dividing early and late EECs</bold>
###xml 52 53 52 53 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 284 285 284 285 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 448 449 448 449 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 516 521 516 521 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">upper</italic>
###xml 575 586 575 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">lower panel</italic>
A six-gene signature dividing early and late EECs. (A) Further narrowing down the existing gene signature to fewer genes. When probe sets were ranked by their signal-to-noise ratios (weights), the top 6 features form the smallest panel which can give the best classification effect. (B) A prediction strength (PS) plot shows the prediction strength of these 6 genes. They give the same classification effect as that of the 217-probeset signature. (C) Signature evaluation by a testing data set. A lowest error rate (upper) and best classification effect (shown by a PS plot; lower panel) was achieved.
###end p 39
###begin p 40
Gene annotations of the six-gene signature.
###end p 40
###begin title 41
Re-activation of epithelial stem cell genes in advanced EECs
###end title 41
###begin p 42
###xml 161 163 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
###xml 351 353 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">5A</xref>
###xml 561 563 561 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">5B</xref>
###xml 696 698 696 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">5C</xref>
###xml 770 771 770 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2</xref>
###xml 803 805 803 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">5D</xref>
###xml 903 907 903 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">5C-D</xref>
###xml 966 968 966 968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">5B</xref>
Since our main goal is to identify EpiSC genes in EECs, we compared the gene expression profiles of EEC tissues of all 4 stages to that of normal CD133+ EpiSCs [39]. When the 217 genes distinguishing early and late EECs were applied to compare the relationships between EECs and EpiSCs, clearly EpiSCs have a closest relationship to late EECs (Figure 5A). This impression is strengthened by calculating the average linkage distances between sample groups. Compared with early EECs, EEC of both Stages III and IV are closer to EpiSCs to a similar extent (Figure 5B), suggesting the re-expression of EpiSC features in late EECs. A total of 26 EpiSC genes are overexpressed in advanced EECs (Figure 5C). Also, genes down-regulated in late EECs (the 77 probe sets in Figure 2) are absence in EpiSCs (Figure 5D). Most early EECs clustered together and expressed the intermediate level of EpiSC genes (Figure 5C-D), consistent with the distances analysis result in Figure 5B.
###end p 42
###begin p 43
###xml 0 63 0 63 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Expression of EpiSC gene patterns in EECs, especially late ones</bold>
###xml 66 67 66 67 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 279 280 279 280 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 430 431 430 431 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 615 616 615 616 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
Expression of EpiSC gene patterns in EECs, especially late ones. (A) Relationships between normal endometrium, EECs of different stages in the training data set and epithelial stem cells (EpiSCs). This MDS plot was drawn by the 217 features differentiating early and late EECs. (B) Average linkage distances between tissues and EpiSCs. The same 217 probe sets were used. The confidence limits shown represent the standard error. (C) A heat map shows genes overexpressed in both EpiSCs and late EECs. Gene symbols of these genes are shown. Genes associate with tumor malignancy or stem cell biology are underlined. (D) A heat map shows the distribution patterns of the 77 probe sets down-regulated in late EECs. These genes are also absence in EpiSCs.
###end p 43
###begin title 44
Discussion
###end title 44
###begin p 45
###xml 595 597 595 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 598 600 598 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 601 603 601 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 913 914 913 914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1</xref>
###xml 576 583 <span type="species:ncbi:9606">patient</span>
EEC still ranks one of the most fatal female cancers worldwide and disease progression very often accompany with worse clinical outcomes and treatment failure. Identifying genes or canonical pathways associated with advanced cancer can help to unmask the mechanisms of tumor malignancy as well as provide us with novel drug targets. It has been recognized clinically that cancer cells, especially the advanced and metastatic ones, possess characters reminiscent of those of normal stem cells. The degree of stem cell gene expression correlates with pivotal tumor features and patient prognosis [10,11,13]. Hence, identifying shared genes between late EECs and stem cells will provide new insights into cancer biology, as well as new prognosis markers and therapeutic targets. In this study, we identified a 217-probeset signature which could distinguish late (stages III-IV) from early (stages I-II) EECs (Figure 1). More low stage disease array data than high stage ones were obtained, which may partly due to the fact that the early diagnosis takes place in almost 90% of EEC clinically. We combined primary and metastatic late EEC samples in one group since their molecular profiles are indistinguishable (not shown). Prostate EpiSCs were used as a comparative group since array data for endometrial stem cells is not available yet. Nevertheless, prostate CD133+ cells are still epithelial stem cells and therefore good controls. Other EpiSC data should reproduce part of our findings.
###end p 45
###begin p 46
###xml 294 296 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">5C</xref>
###xml 345 346 345 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2</xref>
###xml 398 400 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">5D</xref>
###xml 491 493 491 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">5C</xref>
###xml 829 831 829 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B40">40</xref>
###xml 953 955 953 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41">41</xref>
###xml 1074 1076 1074 1076 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B42">42</xref>
###xml 1148 1150 1148 1150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B43">43</xref>
###xml 1285 1287 1285 1287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B44">44</xref>
###xml 1473 1475 1473 1475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B45">45</xref>
###xml 1740 1742 1740 1742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B46">46</xref>
###xml 1364 1372 <span type="species:ncbi:9606">patients</span>
###xml 1463 1471 <span type="species:ncbi:9606">patients</span>
###xml 1624 1628 <span type="species:ncbi:10090">mice</span>
Our results reveal a previously unaware link between genes associated with EpiSC identity and the histopathological traits of EECs. It is possible that these genes contribute to the stem cell-like phenotypes of late EECs. A total of 26 EpiSC genes were found overexpressed in late EECs (Figure 5C), and genes down-regulated in late EECs (Figure 2; 77 probe sets) are also absence in EpiSCs (Figure 5D). Among those 26 overexpressed genes there are famous oncogenes or stemness genes (Figure 5C, underlined). ADAM17 (A Disintegrin and A Metalloproteinase 17), also known as tumor necrosis factor-alpha converting enzyme (TACE) or less commonly CD156q, is a therapeutic target in multiple diseases since major contemporary pathologies like cancer, inflammatory and vascular diseases seem to be connected to its cleavage abilities [40]. CAP1 (adenylate cyclase-associated protein 1) overexpressed in pancreatic cancers is involved in cancer cell motility [41]. CAPG (capping protein (actin filament), gelsolin-like) also contributes in the motility of pancreatic cancer cells [42]. PDCD10 (CCM3) is involved in cerebral cavernous malformations (CCM) [43] and is found to interact with Ste20-related kinase MST4 to promote cell growth and transformation via modulation of the ERK pathway [44]. PSEN1 (presenilin 1) is involved in apoptosis, overexpressed in high-risk patients with stage I non-small cell lung cancer (NSCLC), and is in a prognosis signature of NSCLC patients [45]. SENP2 (SUMO-specific protease 2) is highly expressed in trophoblast cells that are required for placentation, and targeted disruption of SENP2 in mice reveals its essential role in development of all three trophoblast layers via modulating the Mdm2-p53 pathway [46]. The appearance of these known oncogenes or stemness genes in our data supports the reliability of our gene lists. The roles of EpiSC genes in both epithelial stem cell biology and EEC malignancy will be addressed further.
###end p 46
###begin p 47
###xml 365 367 365 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 500 502 500 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B47">47</xref>
###xml 638 640 638 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B48">48</xref>
###xml 279 287 <span type="species:ncbi:9606">patients</span>
###xml 305 313 <span type="species:ncbi:9606">patients</span>
Several genes were previous suggested to be tumor suppressors. CSTA (cystatin A, or stefin A), a cysteine proteinases inhibitor, is implicated in preventing local and metastatic tumor spread of cancers. The risk of disease recurrence and disease-related death was thus higher in patients with low CSTA in patients with squamous cell carcinoma of the head and neck [30]. NPAS2 (neuronal PAS domain protein 2) is a circadian gene as well as a putative tumor suppressor involved in DNA damage response [47]. PHC3 (polyhomeotic homolog 3), a component of the hPRC-H complex, associates with E2F6 during G0 and is lost in osteosarcoma tumors [48]. Validating their expression in different stages of EECs by further immunohistochemstry study will not only provide novel malignancy mechanisms but will also present new drug targets.
###end p 47
###begin p 48
###xml 772 773 772 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">4</xref>
###xml 1079 1081 1079 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B49">49</xref>
###xml 1082 1084 1082 1084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B50">50</xref>
###xml 1431 1432 1431 1432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 875 882 <span type="species:ncbi:9606">patient</span>
###xml 1181 1189 <span type="species:ncbi:9606">patients</span>
###xml 1361 1369 <span type="species:ncbi:9606">patients</span>
###xml 1481 1489 <span type="species:ncbi:9606">patients</span>
In the past few years, much effort has been put to explore the mechanisms and additional molecular markers for predicting prognosis of EECs by using high-throughput genomics technology. Gene expression microarray (GEM) is a popular platform among all of those high-throughput genomics techniques. In this study we applied GEM and machine learning algorithms to filtrate out a 217-probeset signature for disease diagnosis. Many of the filtrated genes have been linked to tumor progression and malignancy, supporting the reliability of our array data. Moreover, we narrowed down this 217-probeset profile to a six-gene mini-signature for the differentiation of early to late EECs in the training set. This signature can be validated by an independent testing cohort (Figure 4). Owing to the small gene number of this signature, it is now possible to check their mRNA levels in patient tissues by real-time PCR in regular clinical labs. Recently a five-gene profile and a five-microRNA signature are identified for the prediction of clinical outcomes in non-small-cell lung cancer [49,50]. Whether our six-gene signature can be correlated with relapse-free and overall survival among patients with EEC is unclear and awaited to be elucidated. Also, whether the protein expression levels of these 6 genes correlate with those of mRNAs is unclear. Since most of the patients in either training or testing data set were Caucasian (Table 1), whether this gene signature can be applied in patients with various genetic backgrounds should also be studied.
###end p 48
###begin p 49
###xml 140 141 140 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1</xref>
###xml 143 144 143 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">2</xref>
###xml 537 545 537 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ </italic>
###xml 553 555 553 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 556 558 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B51">51</xref>
###xml 664 666 664 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 667 669 667 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B51">51</xref>
###xml 946 948 946 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B52">52</xref>
###xml 1174 1176 1174 1176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B53">53</xref>
###xml 153 161 <span type="species:ncbi:9606">patients</span>
###xml 361 366 <span type="species:ncbi:9606">human</span>
###xml 739 744 <span type="species:ncbi:10090">mouse</span>
###xml 810 815 <span type="species:ncbi:10090">mouse</span>
###xml 1327 1332 <span type="species:ncbi:9606">human</span>
###xml 1411 1419 <span type="species:ncbi:9606">patients</span>
###xml 1643 1651 <span type="species:ncbi:9606">patients</span>
In our datasets we noticed that few early EEC cases expressed already late EEC genes and therefore could not be classified correctly (Figs. 1, 2). Since patients with late and metastatic EEC tend to have poor prognosis, whether these unusual early cases possess worse clinical outcomes is an interesting issue. It has been suggested that prognosis potential of human tumors is inherited in early lesions. For example, the gene expression patterns in metastatic colorectal carcinoma are readily distinguishable from those associated with in situ tumors [24,51]. A subset of primary tumors resembled metastatic tumors with respect to this gene-expression signature [24,51]. Very recently Varmus and colleagues showed that when untransformed mouse mammary cells were introduced into the systemic circulation of a mouse, those cells can bypass transformation at the primary site, form long-term residence in the lungs but do not form ectopic tumors [52]. Husemann et al. also observed that systemic spread can be an early step in breast cancer. Tumor cells can disseminate systemically from earliest epithelial alterations and form and micrometastasis in bone marrow and lungs [53]. Therefore, release from dormancy of early-disseminated cancer cells may frequently account for metachronous metastasis. The metastatic potential of human tumors is encoded in the bulk of a primary tumor and, at least in a subset of patients, metastatic capability in cancers is an inherent feature. Our EEC gene signatures therefore hold the potential of being a novel prognosis panel. More advanced therapy and clinical follow-up should be applied on early stage patients with molecular feature similar to that of EpiSC.
###end p 49
###begin p 50
###xml 115 116 115 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">5</xref>
###xml 401 403 401 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">5A</xref>
###xml 405 409 405 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">5C-D</xref>
###xml 592 594 592 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 595 597 595 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 1254 1256 1254 1256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1D</xref>
###xml 1258 1260 1258 1260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">5C</xref>
###xml 1325 1332 1325 1332 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
In advanced EECs, tumor tissues express more genes abundant in CD133+ EpiSC and acquired a stem cell trait (Figure 5). The expression of these EpiSC genes in late EECs may due to the re-expression of EpiSC features in late stage EECs, i.e., further mutations and stem cell gene reactivation in certain early EECs. The intermediate EpiSC gene expression level in early EECs supports this point (Figure 5A &5C-D). Recent studies demonstrated that EMT contributes to the acquisition of stem cell traits in cancer cells and the induction of EMT inducer Snail results in stemness gene expression [14,15]. Whether EMT also contributes in EEC progression and metastasis is an interesting issue to follow. However, we did not rule out the possibility that certain late EECs may arise from an independent rapidly progressing cancer utilizing stemness molecular pathways. According to the tumor stem cell theory, cancer cells may be originated from different cancer stem cells acquiring distinctive oncogenic mutations. Certain early EECs have the capacity to progress to late stage disease may due to a mechanism that they arose from the same mutated progenitor cells as late EECs. The observation that several early EEC cases express EpiSC genes already (Figure 1D &5C) favors the later hypotheses. These 2 situations may both exist in vivo, but our profiling work cannot favor any of them yet. Nevertheless, genes filtrated here will provide clinicians novel prognosis markers and therapeutic targets.
###end p 50
###begin title 51
Conclusions
###end title 51
###begin p 52
###xml 341 342 341 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T5">5</xref>
###xml 772 774 772 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">5C</xref>
###xml 835 837 835 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">5C</xref>
###xml 849 850 849 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">3</xref>
###xml 852 853 852 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T4">4</xref>
###xml 855 856 855 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T5">5</xref>
###xml 858 859 858 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T6">6</xref>
###xml 861 862 861 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T7">7</xref>
In summary, here we reveal distinct epithelial stem cell traits and gene expression patterns in late EECs and some of these genes hold the potential of being novel drug targets. Drugs targeting MAP kinase pathway, for example, may be applied for the treatment of late EEC since this canonical pathway is significantly up in late EECs (Table 5). Since applying a statistical analysis of gene ontology terms is the reliance on prior knowledge of the biological activity of each differentially expressed gene, the enrichment of genes associated with specific pathways may be a consequence of intense research in such areas. Hence, new canonical pathways may still exist and may serve as candidate therapeutic targets. Function of the filtrated KIAA (such as KIAA0323, Figure 5C) and LOC series of anonymous ESTs (such as C20orf24, Figure 5C) in Tables 3, 4, 5, 6, 7 should be studied and their roles in tumor malignancy, chemoresistance and EpiSC stemness are awaited to be elucidated. Further studies to prove the prognosis values and therapeutic potentials of the identified genes, especially those also present in epithelial stem cells, should lead to a better understanding of EEC and EpiSC biology and the susceptibilities of late EECs to treatment.
###end p 52
###begin title 53
Methods
###end title 53
###begin title 54
Microarray data sets
###end title 54
###begin p 55
###xml 200 202 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B39">39</xref>
All array data were implemented by the Affymetrixtrade mark HG-U133 Plus 2.0 GeneChip. Array data of normal CD133+ epithelial stem cells, which were used as a normal counterpart of cancer stem cells [39], isolated from benign prostatic hyperplasia were downloaded from the ArrayExpress database at the European Bioinformatics Institute (; Accession No. E-MEXP-993; array data files 1325504978.cel, 1325505459.cel and 1325505089.cel were used).
###end p 55
###begin p 56
###xml 367 368 367 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 425 430 <span type="species:ncbi:9606">Human</span>
The gene expression profiles of EEC tissues of different stages were generated by the International Genomics Consortium (IGC) under the expO (Expression Project for Ontology) project and were downloaded from Gene Expression Omnibus (GEO ; GSE2109). EEC array data were divided into training (n = 33; incl. all 4 stages) and testing cohorts (n = 15) (details in Table 1). Array data of normal endometrium controls were from a Human body index dataset in GEO (GSE7307).
###end p 56
###begin title 57
Array data processing
###end title 57
###begin p 58
###xml 57 59 57 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 369 370 369 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 451 453 451 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 561 562 561 562 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 592 593 592 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q</italic>
###xml 704 706 704 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 707 709 707 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B54">54</xref>
###xml 771 773 771 773 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B55">55</xref>
###xml 989 991 989 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B56">56</xref>
###xml 992 994 992 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B57">57</xref>
Feature selection was performed as previously described [22]. Briefly, the default robust multichip average (RMA) settings were used to background correct, normalize and summarize all expression values using the 'affy' package of the Bioconductor suite of software  for the R statistical programming language. A t-statistic was calculated as normal for each gene and a p-value then calculated using a modified permutation test in the "LIMMA" package [22]. To control the multiple testing errors, a false discovery rate (FDR) algorithm was then applied to these p-values to calculate a set of q-values: thresholds of the expected proportion of false positives, or false rejections of the null hypothesis [22,54]. Gene annotation was performed by the ArrayFusion web tool [55]. Gene enrichment analysis was performed by the Gene Ontology (GO) database using the DAVID Bioinformatics Resources 2008 interface , a graph theory evidence-based method to agglomerate gene or protein identifiers [56,57].
###end p 58
###begin title 59
Bioinformatics analysis
###end title 59
###begin p 60
###xml 130 132 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 230 232 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 349 351 349 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 608 610 608 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 944 946 944 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 1043 1045 1043 1045 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
The discrimination power of filtrated genes was evaluated by a machine-learning approach combining the weighted voting algorithm [24] and leave-one-out cross-validation (LOOCV). This approach has been integrated in our Java tool [25]. In brief, the uploaded genes are ranked according to the absolute values of corresponding signal-to-noise scores [24] in a descending order. Genes are included into a signature one at a time based on the order of ranking. The error rate for each new signature is estimated by the weighted voting algorithm and LOOCV and can be monitored by an error rate distribution plot [25]. Based on the error rate information, we then selected an appropriate composition of discriminating genes with the lowest error rate. Once a signature is defined, the result of prediction strength (PS) analysis for each sample was shown. The PS values range from -1 to +1, where higher absolute values reflect stronger predictions [25]. An overview of the results for samples in different groups was then illustrated by a PS plot [25].
###end p 60
###begin p 61
###xml 367 369 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
Classical multidimensional scaling (MDS) is performed by the standard function of the R program to provide a visual impression of how the various sample groups are related. The average linkage distance between samples is calculated by the Pearson correlation subtracted from unity to provide bounded distances in the range (0, 2), as described in our previous study [22]. The distance between two groups of samples is calculated using the average linkage measure (the mean of all pair-wise distances (linkages) between members of the two groups concerned). The standard error of the average linkage distance between two groups (the standard deviation of pair-wise linkages divided by the square root of the number of linkages) is quoted when inter-group distances are compared in the text.
###end p 61
###begin title 62
Immunohistochemical staining
###end title 62
###begin p 63
###xml 570 572 570 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
Staining was performed on formalin-fixed, paraffin-embedded specimens using anti-ERBB2 primary antibody (DAKO, Carpinteria, CA, USA). Scoring was performed as following. 0: undetectable staining or membrane staining in <10% of the tumor cells. 1+: faint and incomplete membrane staining in >10% of the tumor cells; 2+: weak to moderate complete membrane staining in >10% of the tumor cells; 3+: strong complete membrane staining observed in >10% of the tumor cells. ERBB2 protein expression was categorized as negative (scores 0 and 1+), or positive (scores 2+ and 3+) [29].
###end p 63
###begin title 64
Authors' contributions
###end title 64
###begin p 65
SJC, TYW, and HWW designed the study project. SJC and TYW collected microarray data sets and EEC materials. SJC, TYW, CYT, and TFW executed project plan and data analysis. SJC, TYW, MDC, and HWW carried out data interpretation and discussion. SJC wrote the manuscript. Then HWW modified it. All authors read and approved the final manuscript.
###end p 65
###begin title 66
Supplementary Material
###end title 66
###begin title 67
Additional file 1
###end title 67
###begin p 68
###xml 0 48 0 48 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">The discrimination ability of the 678 probe sets</bold>
The discrimination ability of the 678 probe sets. Prediction power of the 678 probe sets differentiating early and late stage samples, as well as discriminating normal endometrium and tumor tissues.
###end p 68
###begin p 69
Click here for file
###end p 69
###begin title 70
Additional file 2
###end title 70
###begin p 71
###xml 0 40 0 40 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">The annotation of probed genes and cDNAs</bold>
The annotation of probed genes and cDNAs. Complete data of analyzed arrays and clustered genes/cDNAs.
###end p 71
###begin p 72
Click here for file
###end p 72
###begin title 73
Acknowledgements
###end title 73
###begin p 74
The authors acknowledge the efforts of IGC and expO. This work is supported by the Mackay Memorial Hospital (MMH-HB-97-05), the National Health Research Institute (NHRI-EX97-9704BI), the National Science Council (NSC97-3111-B-010-004 and NSC98-2320-B-010-020-MY3), Taipei Veterans General Hospital Research Fund, VGHUST Joint research Program, Tsou's Foundation (V98ER2-003), and Yang-Ming University (a grant from Ministry of Education, Aim for the Top University Plan).
###end p 74
###begin article-title 75
Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells
###end article-title 75
###begin article-title 76
Metastasis and stem cell pathways
###end article-title 76
###begin article-title 77
Review paper: cancer stem cells and cancer nonstem cells: from adult stem cells or from reprogramming of differentiated somatic cells
###end article-title 77
###begin article-title 78
Stem cells, cancer, and cancer stem cells
###end article-title 78
###begin article-title 79
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines
###end article-title 79
###begin article-title 80
Medulloblastoma can be initiated by deletion of Patched in lineage-restricted progenitors or stem cells
###end article-title 80
###begin article-title 81
Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma
###end article-title 81
###begin article-title 82
Cancer induction by restriction of oncogene expression to the stem cell compartment
###end article-title 82
###begin article-title 83
###xml 12 17 <span type="species:ncbi:9606">human</span>
Creation of human tumour cells with defined genetic elements
###end article-title 83
###begin article-title 84
###xml 72 77 <span type="species:ncbi:10090">mouse</span>
###xml 105 110 <span type="species:ncbi:9606">human</span>
Conserved mechanisms across development and tumorigenesis revealed by a mouse development perspective of human cancers
###end article-title 84
###begin article-title 85
###xml 37 42 <span type="species:ncbi:10090">mouse</span>
###xml 69 74 <span type="species:ncbi:9606">human</span>
Overlapping gene expression in fetal mouse intestine development and human colorectal cancer
###end article-title 85
###begin article-title 86
###xml 80 85 <span type="species:ncbi:10090">mouse</span>
###xml 109 114 <span type="species:ncbi:9606">human</span>
Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer
###end article-title 86
###begin article-title 87
###xml 90 95 <span type="species:ncbi:9606">human</span>
An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors
###end article-title 87
###begin article-title 88
The epithelial-mesenchymal transition generates cells with properties of stem cells
###end article-title 88
###begin article-title 89
Generation of breast cancer stem cells through epithelial-mesenchymal transition
###end article-title 89
###begin article-title 90
Molecular carcinogenesis of endometrial cancer
###end article-title 90
###begin article-title 91
Endometrial cancer
###end article-title 91
###begin article-title 92
Crypt stem cells as the cells-of-origin of intestinal cancer
###end article-title 92
###begin article-title 93
Prominin 1 marks intestinal stem cells that are susceptible to neoplastic transformation
###end article-title 93
###begin article-title 94
###xml 43 48 <span type="species:ncbi:9606">human</span>
OLFM4 is a robust marker for stem cells in human intestine and marks a subset of colorectal cancer cells
###end article-title 94
###begin article-title 95
Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma
###end article-title 95
###begin article-title 96
Functional network reconstruction reveals somatic stemness genetic maps and dedifferentiation-like transcriptome reprogramming induced by GATA2
###end article-title 96
###begin article-title 97
Molecular classification of cancer: class discovery and class prediction by gene expression monitoring
###end article-title 97
###begin article-title 98
A molecular signature of metastasis in primary solid tumors
###end article-title 98
###begin article-title 99
Signature Evaluation Tool (SET): a Java-based tool to evaluate and visualize the sample discrimination abilities of gene expression signatures
###end article-title 99
###begin article-title 100
###xml 119 126 <span type="species:ncbi:9606">patient</span>
Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival
###end article-title 100
###begin article-title 101
###xml 83 88 <span type="species:ncbi:9606">human</span>
Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas
###end article-title 101
###begin article-title 102
Prognostic factors in endometrial carcinoma
###end article-title 102
###begin article-title 103
An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study
###end article-title 103
###begin article-title 104
###xml 118 126 <span type="species:ncbi:9606">patients</span>
Prognostic significance of cysteine proteinases cathepsins B and L and their endogenous inhibitors stefins A and B in patients with squamous cell carcinoma of the head and neck
###end article-title 104
###begin article-title 105
Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling
###end article-title 105
###begin article-title 106
Molecular pathogenesis and prognostic factors in endometrial carcinoma
###end article-title 106
###begin article-title 107
Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma
###end article-title 107
###begin article-title 108
Methylation profiling in acute myeloid leukemia
###end article-title 108
###begin article-title 109
Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature
###end article-title 109
###begin article-title 110
Cell biology of cancer: BRCA1 and sister chromatid pairing reactions?
###end article-title 110
###begin article-title 111
Gene expression profiling differentiates germ cell tumors from other cancers and defines subtype-specific signatures
###end article-title 111
###begin article-title 112
KITENIN recruits Dishevelled/PKC delta to form a functional complex and controls the migration and invasiveness of colorectal cancer cells
###end article-title 112
###begin article-title 113
###xml 29 34 <span type="species:ncbi:9606">human</span>
Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions
###end article-title 113
###begin article-title 114
ADAM17 as a therapeutic target in multiple diseases
###end article-title 114
###begin article-title 115
Adenylate cyclase-associated protein 1 overexpressed in pancreatic cancers is involved in cancer cell motility
###end article-title 115
###begin article-title 116
Pancreatic cancer cells overexpress gelsolin family-capping proteins, which contribute to their cell motility
###end article-title 116
###begin article-title 117
Genetics of cavernous angiomas
###end article-title 117
###begin article-title 118
PDCD10 interacts with Ste20-related kinase MST4 to promote cell growth and transformation via modulation of the ERK pathway
###end article-title 118
###begin article-title 119
###xml 49 57 <span type="species:ncbi:9606">patients</span>
A gene expression signature predicts survival of patients with stage I non-small cell lung cancer
###end article-title 119
###begin article-title 120
SUMO-specific protease 2 is essential for modulating p53-Mdm2 in development of trophoblast stem cell niches and lineages
###end article-title 120
###begin article-title 121
The circadian gene NPAS2, a putative tumor suppressor, is involved in DNA damage response
###end article-title 121
###begin article-title 122
PHC3, a component of the hPRC-H complex, associates with E2F6 during G0 and is lost in osteosarcoma tumors
###end article-title 122
###begin article-title 123
A five-gene signature and clinical outcome in non-small-cell lung cancer
###end article-title 123
###begin article-title 124
MicroRNA signature predicts survival and relapse in lung cancer
###end article-title 124
###begin article-title 125
Gene expression profiles of primary breast tumors maintained in distant metastases
###end article-title 125
###begin article-title 126
###xml 41 46 <span type="species:ncbi:10090">mouse</span>
Seeding and propagation of untransformed mouse mammary cells in the lung
###end article-title 126
###begin article-title 127
Systemic spread is an early step in breast cancer
###end article-title 127
###begin article-title 128
###xml 28 33 <span type="species:ncbi:9606">human</span>
Genetic network analysis of human CD34+ hematopoietic stem/precursor cells
###end article-title 128
###begin article-title 129
ArrayFusion: a web application for multi-dimensional analysis of CGH, SNP and microarray data
###end article-title 129
###begin article-title 130
The Gene Ontology (GO) database and informatics resource
###end article-title 130
###begin article-title 131
DAVID: Database for Annotation, Visualization, and Integrated Discovery
###end article-title 131

